Mobile

Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis

Update Il y a 4 ans
Reference: EUCTR2016-001490-33

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.

Inclusion criteria

  • RAS and B-RAF wild-type metastatic colorectal cancer

Links